Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Scott SA, et al. Among authors: hulot js. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. Clin Pharmacol Ther. 2013. PMID: 23698643 Free PMC article.
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Scott SA, et al. Among authors: hulot js. Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Clin Pharmacol Ther. 2011. PMID: 21716271 Free PMC article.
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS. Scott SA, et al. Among authors: hulot js. Clin Pharmacol Ther. 2016 Sep;100(3):287-94. doi: 10.1002/cpt.401. Epub 2016 Jun 20. Clin Pharmacol Ther. 2016. PMID: 27213804 Free PMC article.
The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics.
Gottesman O, Scott SA, Ellis SB, Overby CL, Ludtke A, Hulot JS, Hall J, Chatani K, Myers K, Kannry JL, Bottinger EP. Gottesman O, et al. Among authors: hulot js. Clin Pharmacol Ther. 2013 Aug;94(2):214-7. doi: 10.1038/clpt.2013.72. Epub 2013 Apr 3. Clin Pharmacol Ther. 2013. PMID: 23588317 Free PMC article. No abstract available.
Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.
Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, Funck-Brentano C, Gaussem P. Hulot JS, et al. J Thromb Haemost. 2010 Mar;8(3):610-3. doi: 10.1111/j.1538-7836.2009.03729.x. Epub 2009 Dec 21. J Thromb Haemost. 2010. PMID: 20040040 Free article. Clinical Trial. No abstract available.
Clinical implications of neuropharmacogenetics.
Corvol JC, Devos D, Hulot JS, Lacomblez L. Corvol JC, et al. Among authors: hulot js. Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):482-97. doi: 10.1016/j.neurol.2015.04.003. Epub 2015 May 23. Rev Neurol (Paris). 2015. PMID: 26008819 Review.
300 results